Pharmacokinetic analysis and simplified uptake measures for tumour lesion [¹⁸F]F-AraG PET imaging in patients with non-small cell lung cancer.

ABSTRACT:

Introduction

The novel positron emission tomography (PET) imaging tracer, [¹⁸F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [¹⁸F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.

Methods

Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input f

SUBMITTER: Wijngaarden JE 

PROVIDER: S-EPMC11732896 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature